Allogene Therapeutics (NASDAQ:ALLO) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $8.00 price target on the stock.

Several other brokerages also recently commented on ALLO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

Allogene Therapeutics Price Performance

ALLO stock opened at $1.71 on Wednesday. The firm has a market cap of $384.29 million, a PE ratio of -1.74 and a beta of 0.51. Allogene Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.78. The firm has a 50 day simple moving average of $1.36 and a 200 day simple moving average of $1.26.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. As a group, sell-side analysts expect that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total value of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares in the company, valued at approximately $1,608,762.96. This represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.20% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its holdings in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after acquiring an additional 3,747,397 shares in the last quarter. Millennium Management LLC grew its stake in Allogene Therapeutics by 125.6% in the third quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock valued at $4,204,000 after purchasing an additional 1,887,302 shares in the last quarter. Two Sigma Investments LP increased its position in Allogene Therapeutics by 109.7% in the 3rd quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock worth $4,196,000 after purchasing an additional 1,770,419 shares during the last quarter. UBS Group AG raised its stake in shares of Allogene Therapeutics by 75.1% during the 3rd quarter. UBS Group AG now owns 3,571,157 shares of the company’s stock worth $4,428,000 after purchasing an additional 1,532,238 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in shares of Allogene Therapeutics by 23.8% during the 3rd quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock worth $8,778,000 after purchasing an additional 1,360,168 shares in the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

More Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: UBS initiated coverage with a Buy and $8 price target, citing upside to ALLO’s pipeline and potential validation of allogeneic CAR‑T if upcoming readouts are positive. UBS initiates coverage of Allogene Therapeutics (ALLO) with buy recommendation
• Positive Sentiment: Citizens JMP upgraded ALLO from Market Perform to Outperform and set a $5 target — another analyst vote that increases the stock’s visible upside and likely contributed to short‑term buying. Benzinga coverage of analyst action
• Positive Sentiment: Allogene’s own press release frames 2026 as a program‑defining year with multiple first‑half clinical readouts planned across oncology and autoimmune programs — this set of near‑term milestones increases binary upside if data are positive. Allogene Therapeutics Positions 2026 as a Program-Defining Year
• Neutral Sentiment: AAII explains the immediate price move, attributing it to the new analyst coverage and the company’s 2026 roadmap; useful read for traders seeking the narrative behind today’s jump. Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 18.13%
• Neutral Sentiment: Zacks compares ALLO to medical‑sector peers and discusses sector‑level performance this year — helpful context but not a direct catalyst. Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
• Neutral Sentiment: Globe and Mail ran an analysts‑insights piece that includes ALLO — provides additional perspective but no new company data. Analysts Offer Insights on Healthcare Companies

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.